IBDEI0W3 ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,15048,1,4,0)
 ;;=4^E11.9
 ;;^UTILITY(U,$J,358.3,15048,2)
 ;;=^5002666
 ;;^UTILITY(U,$J,358.3,15049,0)
 ;;=E10.9^^56^638^6
 ;;^UTILITY(U,$J,358.3,15049,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15049,1,3,0)
 ;;=3^DM Type 1 w/o Complications
 ;;^UTILITY(U,$J,358.3,15049,1,4,0)
 ;;=4^E10.9
 ;;^UTILITY(U,$J,358.3,15049,2)
 ;;=^5002626
 ;;^UTILITY(U,$J,358.3,15050,0)
 ;;=E11.65^^56^638^15
 ;;^UTILITY(U,$J,358.3,15050,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15050,1,3,0)
 ;;=3^DM Type 2 w/ Hyperglycemia
 ;;^UTILITY(U,$J,358.3,15050,1,4,0)
 ;;=4^E11.65
 ;;^UTILITY(U,$J,358.3,15050,2)
 ;;=^5002663
 ;;^UTILITY(U,$J,358.3,15051,0)
 ;;=E53.8^^56^638^30
 ;;^UTILITY(U,$J,358.3,15051,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15051,1,3,0)
 ;;=3^Vitamin B Deficiency NEC
 ;;^UTILITY(U,$J,358.3,15051,1,4,0)
 ;;=4^E53.8
 ;;^UTILITY(U,$J,358.3,15051,2)
 ;;=^5002797
 ;;^UTILITY(U,$J,358.3,15052,0)
 ;;=E78.0^^56^638^29
 ;;^UTILITY(U,$J,358.3,15052,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15052,1,3,0)
 ;;=3^Pure Hypercholesterolemia
 ;;^UTILITY(U,$J,358.3,15052,1,4,0)
 ;;=4^E78.0
 ;;^UTILITY(U,$J,358.3,15052,2)
 ;;=^5002966
 ;;^UTILITY(U,$J,358.3,15053,0)
 ;;=E78.5^^56^638^24
 ;;^UTILITY(U,$J,358.3,15053,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15053,1,3,0)
 ;;=3^Hyperlipidemia,Unspec
 ;;^UTILITY(U,$J,358.3,15053,1,4,0)
 ;;=4^E78.5
 ;;^UTILITY(U,$J,358.3,15053,2)
 ;;=^5002969
 ;;^UTILITY(U,$J,358.3,15054,0)
 ;;=E66.01^^56^638^27
 ;;^UTILITY(U,$J,358.3,15054,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15054,1,3,0)
 ;;=3^Morbid Obesity
 ;;^UTILITY(U,$J,358.3,15054,1,4,0)
 ;;=4^E66.01
 ;;^UTILITY(U,$J,358.3,15054,2)
 ;;=^5002826
 ;;^UTILITY(U,$J,358.3,15055,0)
 ;;=D64.9^^56^638^5
 ;;^UTILITY(U,$J,358.3,15055,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15055,1,3,0)
 ;;=3^Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,15055,1,4,0)
 ;;=4^D64.9
 ;;^UTILITY(U,$J,358.3,15055,2)
 ;;=^5002351
 ;;^UTILITY(U,$J,358.3,15056,0)
 ;;=D68.318^^56^638^23
 ;;^UTILITY(U,$J,358.3,15056,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15056,1,3,0)
 ;;=3^Hemorrhagic Disorder d/t Intrns Circ Anticoag/Antibodies/Inhibitors
 ;;^UTILITY(U,$J,358.3,15056,1,4,0)
 ;;=4^D68.318
 ;;^UTILITY(U,$J,358.3,15056,2)
 ;;=^340504
 ;;^UTILITY(U,$J,358.3,15057,0)
 ;;=D50.9^^56^638^26
 ;;^UTILITY(U,$J,358.3,15057,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15057,1,3,0)
 ;;=3^Iron Deficiency Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,15057,1,4,0)
 ;;=4^D50.9
 ;;^UTILITY(U,$J,358.3,15057,2)
 ;;=^5002283
 ;;^UTILITY(U,$J,358.3,15058,0)
 ;;=D64.81^^56^638^2
 ;;^UTILITY(U,$J,358.3,15058,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15058,1,3,0)
 ;;=3^Anemia d/t Antineoplastic Chemotherapy
 ;;^UTILITY(U,$J,358.3,15058,1,4,0)
 ;;=4^D64.81
 ;;^UTILITY(U,$J,358.3,15058,2)
 ;;=^5002349
 ;;^UTILITY(U,$J,358.3,15059,0)
 ;;=D63.1^^56^638^4
 ;;^UTILITY(U,$J,358.3,15059,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15059,1,3,0)
 ;;=3^Anemia in Chronic Kidney Disease
 ;;^UTILITY(U,$J,358.3,15059,1,4,0)
 ;;=4^D63.1
 ;;^UTILITY(U,$J,358.3,15059,2)
 ;;=^332908
 ;;^UTILITY(U,$J,358.3,15060,0)
 ;;=D62.^^56^638^1
 ;;^UTILITY(U,$J,358.3,15060,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15060,1,3,0)
 ;;=3^Acute Blood Loss Anemia
 ;;^UTILITY(U,$J,358.3,15060,1,4,0)
 ;;=4^D62.
 ;;^UTILITY(U,$J,358.3,15060,2)
 ;;=^267986
 ;;^UTILITY(U,$J,358.3,15061,0)
 ;;=D51.9^^56^638^32
 ;;^UTILITY(U,$J,358.3,15061,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15061,1,3,0)
 ;;=3^Vitamin B12 Deficiency Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,15061,1,4,0)
 ;;=4^D51.9
 ;;^UTILITY(U,$J,358.3,15061,2)
 ;;=^5002289
